




CKD – egfr drop 40% and stage 5 outcomes for no CVD/HF/CKD population Overall population (n=52052, event = 185) 5 + 4-3 2-0 -10 **-**5 **1**0 5 SGLT2i HbA1c benefit 10 -5 5 -10 SGLT2i HbA1c benefit

## CVD outcomes for no CVD population Propensity score matching (n=18554, event = 219) 6-4 -2-0 **-**5 5 10 -10SGLT2i HbA1c benefit -5 5 10 -10


SGLT2i HbA1c benefit







Microvascular complications outcomes for Microvascular complications population Propensity score matching (n=11634, event = 1965)



Microvascular complications outcomes for no Microvascular complications population (n=34524, event = 5228)

